Oncolytics Biotech (Oncolytics Biotech) Cash And Cash Equivalents : $26.02 Mil (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Oncolytics Biotech Cash And Cash Equivalents?

Oncolytics Biotech's quarterly cash and cash equivalents increased from Jun. 2023 ($13.19 Mil) to Sep. 2023 ($29.55 Mil) but then stayed the same from Sep. 2023 ($29.55 Mil) to Dec. 2023 ($26.02 Mil).

Oncolytics Biotech's annual cash and cash equivalents declined from Dec. 2021 ($32.24 Mil) to Dec. 2022 ($8.59 Mil) but then increased from Dec. 2022 ($8.59 Mil) to Dec. 2023 ($26.02 Mil).

Oncolytics Biotech Cash And Cash Equivalents Historical Data

The historical data trend for Oncolytics Biotech's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncolytics Biotech Cash And Cash Equivalents Chart

Oncolytics Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

10.74

24.37

32.24

8.59

26.02

Oncolytics Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															8.59	11.60	13.19	29.55	26.02

Oncolytics Biotech Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Oncolytics Biotech (NAS:ONCY) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Oncolytics Biotech Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Oncolytics Biotech's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncolytics Biotech (Oncolytics Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (NAS:ONCY) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

ONC:Canada

Address

322 11th Avenue S.W, Suite 804, Calgary, AB, CAN, T2R 0C5

Website

https://www.oncolyticsbiotech.com

Oncolytics Biotech Inc is a development-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly as possible and expands its products into commercially valuable new treatment areas as objectives. The primary focus is to advance programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies.